Abeona Therapeutics (NASDAQ:ABEO – Get Rating) had its price objective upped by investment analysts at Cantor Fitzgerald from $22.00 to $40.00 in a note issued to investors on Tuesday, The Fly reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock.

ABEO has been the subject of a number of other reports. Alliance Global Partners assumed coverage on shares of Abeona Therapeutics in a report on Thursday, September 15th. They set a "buy" rating for the company. StockNews.com assumed coverage on shares of Abeona Therapeutics in a report on Wednesday, October 12th. They issued a "sell" rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $55.00.

Abeona Therapeutics Stock Up 7.9 %

Shares of NASDAQ ABEO opened at $4.11 on Tuesday. Abeona Therapeutics has a 52 week low of $2.70 and a 52 week high of $25.45. The firm has a 50-day moving average price of $3.89 and a 200 day moving average price of $4.21. The stock has a market capitalization of $24.45 million, a price-to-earnings ratio of -0.22 and a beta of 1.27.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. AIGH Capital Management LLC lifted its position in Abeona Therapeutics by 341.9% during the first quarter. AIGH Capital Management LLC now owns 5,025,100 shares of the biopharmaceutical company's stock valued at $1,583,000 after buying an additional 3,887,826 shares in the last quarter. Renaissance Technologies LLC lifted its position in Abeona Therapeutics by 3.1% during the second quarter. Renaissance Technologies LLC now owns 2,398,166 shares of the biopharmaceutical company's stock valued at $499,000 after buying an additional 72,350 shares in the last quarter. BlackRock Inc. lifted its position in Abeona Therapeutics by 4.7% during the first quarter. BlackRock Inc. now owns 1,694,624 shares of the biopharmaceutical company's stock valued at $534,000 after buying an additional 76,694 shares in the last quarter. Worth Venture Partners LLC lifted its position in Abeona Therapeutics by 9.5% during the first quarter. Worth Venture Partners LLC now owns 1,244,774 shares of the biopharmaceutical company's stock valued at $392,000 after buying an additional 107,500 shares in the last quarter. Finally, State Street Corp lifted its position in Abeona Therapeutics by 24.6% during the second quarter. State Street Corp now owns 377,402 shares of the biopharmaceutical company's stock valued at $78,000 after buying an additional 74,600 shares in the last quarter.

Abeona Therapeutics Company Profile

(Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Read More

• Get a free copy of the StockNews.com research report on Abeona Therapeutics (ABEO)
• Is Triple-Digit Growth Ahead For Digital Ad Platform Trade Desk?
• EV Maker Lucid Falls On Declining Orders, Rivian Up On Guidance
• DoorDash Outperforms Despite Losses – Is It Time To Buy?
• Analysts Rate DraftKings a Moderate Buy As Growth Slows
• Goodyear Tire & Rubber Stock is Becoming a Mighty Good Bargain

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.